Gerresheimer AG (GXI.DE)
EUR 60.55
(1.94%)
EUR 60.55
(1.94%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 400.56 Million EUR | 7.32% |
| 2022 | 340.19 Million EUR | 20.05% |
| 2021 | 293.09 Million EUR | 0.35% |
| 2020 | 309.25 Million EUR | 9.08% |
| 2019 | 279.55 Million EUR | 2.08% |
| 2018 | 274.3 Million EUR | -3.26% |
| 2017 | 306.83 Million EUR | -2.0% |
| 2016 | 307.78 Million EUR | 15.36% |
| 2015 | 265.72 Million EUR | 7.77% |
| 2014 | 237.65 Million EUR | 10.11% |
| 2013 | 218.7 Million EUR | -2.24% |
| 2012 | 229.07 Million EUR | 7.74% |
| 2011 | 204.33 Million EUR | 3.47% |
| 2010 | 201.78 Million EUR | 14.22% |
| 2009 | 176.29 Million EUR | 1.41% |
| 2008 | 172.29 Million EUR | 0.12% |
| 2007 | 163.55 Million EUR | -71.01% |
| 2006 | 102.85 Million EUR | 12.73% |
| 2005 | 542.12 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 81.17 Million EUR | -33.03% |
| 2024 Q2 | 97.31 Million EUR | 22.69% |
| 2024 Q3 | 101.02 Million EUR | 3.81% |
| 2023 Q3 | 100.44 Million EUR | -7.21% |
| 2023 Q4 | 118.43 Million EUR | 17.92% |
| 2023 FY | - EUR | 7.32% |
| 2023 Q1 | 76.76 Million EUR | -26.2% |
| 2023 Q2 | 108.24 Million EUR | 41.0% |
| 2022 Q3 | 87.59 Million EUR | -0.14% |
| 2022 Q4 | 104.02 Million EUR | 18.75% |
| 2022 FY | - EUR | 20.05% |
| 2022 Q2 | 87.72 Million EUR | 43.86% |
| 2022 Q1 | 60.97 Million EUR | -33.93% |
| 2021 Q2 | 78.58 Million EUR | 50.23% |
| 2021 Q4 | 92.28 Million EUR | 30.46% |
| 2021 FY | - EUR | 0.35% |
| 2021 Q1 | 52.31 Million EUR | -55.08% |
| 2021 Q3 | 70.74 Million EUR | -9.99% |
| 2020 Q1 | 49.85 Million EUR | 380.86% |
| 2020 FY | - EUR | 9.08% |
| 2020 Q4 | 116.45 Million EUR | 49.28% |
| 2020 Q3 | 78.01 Million EUR | -1.6% |
| 2020 Q2 | 79.28 Million EUR | 59.01% |
| 2019 Q4 | -17.75 Million EUR | -125.28% |
| 2019 Q3 | 70.23 Million EUR | -28.93% |
| 2019 Q2 | 98.82 Million EUR | 97.31% |
| 2019 Q1 | 50.08 Million EUR | -51.33% |
| 2019 FY | - EUR | 2.08% |
| 2018 Q1 | 47.5 Million EUR | -47.18% |
| 2018 FY | - EUR | -3.26% |
| 2018 Q3 | 70.58 Million EUR | 1.36% |
| 2018 Q2 | 69.63 Million EUR | 46.58% |
| 2018 Q4 | 102.91 Million EUR | 45.81% |
| 2017 Q1 | 59.25 Million EUR | -20.31% |
| 2017 Q3 | 76.28 Million EUR | 1.81% |
| 2017 Q4 | 89.93 Million EUR | 17.89% |
| 2017 Q2 | 74.93 Million EUR | 26.46% |
| 2017 FY | - EUR | -2.0% |
| 2016 Q3 | 83.48 Million EUR | -7.7% |
| 2016 Q2 | 90.45 Million EUR | 37.34% |
| 2016 Q4 | 74.35 Million EUR | -10.94% |
| 2016 FY | - EUR | 15.36% |
| 2016 Q1 | 65.86 Million EUR | -20.2% |
| 2015 Q4 | 82.53 Million EUR | 36.06% |
| 2015 Q1 | 51.53 Million EUR | -15.16% |
| 2015 Q3 | 60.65 Million EUR | -14.56% |
| 2015 FY | - EUR | 7.77% |
| 2015 Q2 | 70.99 Million EUR | 37.76% |
| 2014 Q1 | 48.2 Million EUR | -2.99% |
| 2014 FY | - EUR | 10.11% |
| 2014 Q4 | 60.74 Million EUR | -3.32% |
| 2014 Q3 | 62.83 Million EUR | -4.61% |
| 2014 Q2 | 65.86 Million EUR | 36.64% |
| 2013 FY | - EUR | -2.24% |
| 2013 Q1 | 47.78 Million EUR | -33.91% |
| 2013 Q2 | 59.66 Million EUR | 24.85% |
| 2013 Q4 | 49.68 Million EUR | -19.68% |
| 2013 Q3 | 61.86 Million EUR | 3.69% |
| 2012 Q4 | 72.3 Million EUR | 27.58% |
| 2012 Q1 | 42.35 Million EUR | -24.85% |
| 2012 FY | - EUR | 7.74% |
| 2012 Q2 | 58.48 Million EUR | 38.09% |
| 2012 Q3 | 56.67 Million EUR | -3.1% |
| 2011 Q2 | 55.97 Million EUR | 33.55% |
| 2011 Q1 | 41.91 Million EUR | -26.69% |
| 2011 Q3 | 58.36 Million EUR | 4.28% |
| 2011 Q4 | 56.36 Million EUR | -3.44% |
| 2011 FY | - EUR | 3.47% |
| 2010 Q3 | 53.75 Million EUR | -4.05% |
| 2010 Q1 | 38.54 Million EUR | -34.35% |
| 2010 Q4 | 57.17 Million EUR | 6.36% |
| 2010 Q2 | 56.02 Million EUR | 45.36% |
| 2010 FY | - EUR | 14.22% |
| 2009 Q2 | 41.29 Million EUR | 7.66% |
| 2009 FY | - EUR | 1.41% |
| 2009 Q1 | 38.35 Million EUR | 0.0% |
| 2009 Q3 | 41.53 Million EUR | 0.6% |
| 2009 Q4 | 58.7 Million EUR | 41.33% |
| 2008 FY | - EUR | 0.12% |
| 2007 FY | - EUR | -71.01% |
| 2006 FY | - EUR | 12.73% |
| 2005 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| SCHOTT Pharma AG & Co. KGaA | 227.64 Million EUR | -75.961% |
| Carl Zeiss Meditec AG | 502.77 Million EUR | 20.328% |
| Fielmann Aktiengesellschaft | 403.8 Million EUR | 0.802% |
| Sartorius Aktiengesellschaft | 920.1 Million EUR | 56.465% |
| Sartorius Aktiengesellschaft | 920.1 Million EUR | 56.465% |